Dr. David Sprenger, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 4140 Mother Lode Dr Ste 104, Shingle Springs, CA 95682 Phone: 530-672-8059 Fax: 530-672-8057 |
News Archive
Bristol-Myers Squibb Company and ZymoGenetics, Inc. today presented final results from a Phase 1b clinical trial of PEG-Interferon lambda administered with ribavirin in relapsed and treatment-naïve hepatitis C virus (HCV) patients.
Bacterial infections usually announce themselves with pain and fever but often can be defeated with antibiotics - and then there are those that are sneaky and hard to beat. Now, scientists have built a new weapon against such pathogens in the form of tiny DNA pyramids.
A research study coordinated by Manel Esteller, researcher at Bellvitge Biomedical Research Institute (IDIBELL) has identified a substance that inhibits cancer growth by activating the so‑called "dark genome" (or non‑coding DNA) and micro‑RNA molecules. The study appears this week in the journal Proceedings of the National Academy of Sciences (PNAS).
Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, confirmed today that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing and the patients enrolled in the trial are continuing to be treated per the protocol.
› Verified 3 days ago